Credit Suisse’s BioMarin Pharmaceuticals BMRN Stock Holding History

Credit Suisse’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-45,200	Closed	-$3.99M	–	3674
2021 Q4	$3.99M	Sell	45,200 -118,100	-72%	-$9.74M	﹤0.01%	2208
2021 Q3	$12.6M	Sell	163,300 -79,900	-33%	-$6.3M	0.01%	1383
2021 Q2	$20.3M	Sell	243,200 -32,000	-12%	-$2.54M	0.01%	1139
2021 Q1	$20.8M	Buy	275,200 +71,300	+35%	+$5.82M	0.01%	1139
2020 Q4	$17.9M	Buy	203,900 +174,700	+598%	+$13.9M	0.01%	1233
2020 Q3	$2.22M	Buy	+29,200	New	+$2.95M	﹤0.01%	2355
2019 Q2	–	Sell	-10,000	Closed	-$888K	–	4090
2019 Q1	$888K	Sell	10,000 -26,000	-72%	-$2.41M	﹤0.01%	2976
2018 Q4	$3.06M	Hold	36,000	–	–	﹤0.01%	1938
2018 Q3	$3.49M	Sell	36,000 -30,000	-45%	-$2.99M	﹤0.01%	1937
2018 Q2	$6.22M	Hold	66,000	–	–	0.01%	1577
2018 Q1	$5.35M	Buy	66,000 +30,000	+83%	+$2.57M	0.01%	1664
2017 Q4	$3.21M	Buy	+36,000	New	+$3.13M	﹤0.01%	2083

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse's BMRN Position: Q1 2024 in Review

Credit Suisse reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.1% in Q1 2024, selling an estimated $2.27M and leaving 286,650 shares worth $25M. The position accounts for 0.02% of the portfolio, ranked #571.

Credit Suisse first reported a position in BMRN in Q2 2013 and has held it in 44 quarters since. The position peaked at $82.9M in Q3 2014. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Credit Suisse held 286,650 shares of BioMarin Pharmaceuticals worth $25M as of Q1 2024.
Credit Suisse sold 25,343 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $2.27M.
BioMarin Pharmaceuticals made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #571 holding.
Credit Suisse first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's BioMarin Pharmaceuticals position peaked at $82.9M in Q3 2014.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.